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Dysfunctional patterns of activation in brain reward net-
works have been suggested as a core element in the patho-
physiology of schizophrenia. However, it remains unclear 
whether this dysfunction is specific to schizophrenia or 
can be continuously observed across persons with differ-
ent levels of nonclinical and clinical symptom expression. 
Therefore, we sought to investigate whether the pattern of 
reward system dysfunction is consistent with a dimensional 
or categorical model of psychosis-like symptom expression. 
23 patients with schizophrenia and 37 healthy control par-
ticipants with varying levels of psychosis-like symptoms, 
separated into 3 groups of low, medium, and high symptom 
expression underwent event-related functional magnetic 
resonance imaging while performing a Cued Reinforcement 
Reaction Time task. We observed lower activation in 
the ventral striatum during the expectation of high vs no 
reward to be associated with higher symptom expression 
across all participants. No significant difference between 
patients with schizophrenia and healthy participants with 
high symptom expression was found. However, connectivity 
between the ventral striatum and the medial orbitofrontal 
cortex was specifically reduced in patients with schizophre-
nia. Dysfunctional local activation of the ventral striatum 
depends less on diagnostic category than on the degree of 
symptom expression, therefore showing a pattern consis-
tent with a psychosis continuum. In contrast, aberrant con-
nectivity in the reward system is specific to patients with 
schizophrenia, thereby supporting a categorical view. Thus, 
the results of the present study provide evidence for both 
continuous and discontinuous neural substrates of symptom 
expression across patients with schizophrenia and the gen-
eral population.
Key words: dimensional symptom expression/psychosis-
like symptom expression/functional magnetic 
resonance imaging/cued reinforcement reaction time 
task/apathy/ventral striatum
Introduction
A growing number of studies suggest that symptoms of 
schizophrenia cannot only be observed in patients suf-
fering from schizophrenia but also in subclinical form 
in persons without a psychotic disorder.1–3 Dimensional 
models of schizophrenia postulate a continuous symp-
tom expression in the general population, where patients 
with schizophrenia lie at the extreme end of the popu-
lation distribution.4,5 However, more recent publications 
have begun to integrate categorical and dimensional 
approaches.6,7
Recent neuroimaging studies have begun to investi-
gate the psychosis continuum on a neural level.8–10 These 
studies have focused on samples defined by subclinical 
psychotic experiences or schizotypal personality traits. 
In these samples, dysfunctions of several brain systems 
were found to be comparable to those in patients with 
schizophrenia, which is consistent with the continuum 
hypothesis. However, there are no studies investigating 
brain mechanisms across different levels of symptom 
expression in both nonclinical participants and patients 
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with schizophrenia, which would be important to address 
the continuum vs category debate.
In this context, a major focus of  interest lies on the 
networks underlying reward processing, especially 
dopaminergic projections with target regions in the 
ventral striatum (VS) and the orbitofrontal cortex 
(OFC).11,12 In unmedicated patients with schizophre-
nia, ventral striatal activation in response to rewarding 
stimuli is reduced in comparison to healthy partici-
pants.13,14 Treatment with atypical antipsychotics seems 
to attenuate differences between patients and controls.15 
Importantly, reduced striatal activation has been asso-
ciated with negative and positive symptoms in patients 
with schizophrenia.14,16–18 Apathy seems to be the nega-
tive symptom most closely related to blunted reward 
processing.17,18 More recently, dysfunctional connec-
tivity within the reward system has been reported in 
patients with schizophrenia.14,19
The aim of the present study was to investigate whether 
dysfunctional neural reward processing could be a sub-
strate of different levels of psychosis-like symptom (PLS) 
expression across the general population and clinical 
symptoms of schizophrenia. For this purpose we mea-
sured neural activity during reward anticipation with a 
modified Cued Reinforcement Reaction Time (CRRT20)-
task. Importantly, we recruited both patients with schizo-
phrenia and healthy participants with varying degrees 
of PLS. The latter group was recruited with a stratified 
sampling procedure to ensure that all levels of PLS were 
adequately represented. Our final sample of participants 
was therefore characterized by a broad distribution of 
both clinical symptoms and subclinical PLS (supplemen-
tary figure S1).
We expected a linear relation between neural reward 
processing and general symptom expression. A  higher 
symptom load should lead to lower activity in the VS dur-
ing the anticipation of rewards. Additionally, we expected 
that apathy would be associated with a reduced activa-
tion of the VS during anticipation of a reward. Finally, 
we investigated connectivity between the VS and other 
regions within the reward system across healthy partici-
pants and patients with schizophrenia.
Methods
Participants
We recruited healthy participants using an internet-
based questionnaire assessing subclinical experiences of 
PLS (Community Assessment of Psychic Experiences, 
[CAPE21]). The CAPE has been developed to measure 
positive (20 items), negative (14 items), and depressive 
symptoms (8 items) in the general population and has been 
found to possess good validity and reliability.22 The level 
of symptom expression in participants was determined 
by combining the frequency score of negative, positive, 
and depressive symptoms. Out of the 350 participants 
who filled out the questionnaire, 12 healthy participants 
with a low PLS level (at least 1 SD below the mean), 14 
healthy participants with an average PLS level (deviation 
of less than 1 SD from the mean), and11 healthy par-
ticipants with a high PLS level (at least 1 SD above the 
mean) were invited to participate in an functional mag-
netic resonance imaging (fMRI) study (supplementary 
figure S1). Healthy participants had to be right-handed 
and without any current Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV) 
psychiatric disorder and history of psychotic disorder, 
psychopharmacological treatment, drug abuse, or neu-
rological disorder. Lifetime depressive episodes were 
reported by 2 subjects in the medium expression group 
and 4 subjects in the high expression group. Additionally, 
23 patients with schizophrenia or schizoaffective disor-
der were recruited. Patients had to fulfill clinical DSM-IV 
criteria and the diagnosis was confirmed by M.I.N.I.23 
Thus, patients were recruited based on diagnosis and 
not on CAPE scores. Patients were excluded if  another 
axis-I disorder was present. All patients were medicated 
with atypical antipsychotics, 5 patients were additionally 
treated with mood stabilizers, and 7 patients were addi-
tionally treated with antidepressants. Chlorpromazine 
equivalents were calculated following the guidelines pro-
vided by Andreasen and colleagues24 as well as Gardner 
and colleagues.25 The present study complies with the 
declaration of Helsinki, version 2008, and was approved 
by the Ethics Committee of the Medical School of the 
University of Heidelberg. All participants provided writ-
ten informed consent.
Psychopathological Assessment
In both groups, negative symptoms were measured using 
the Scale for the Assessment of  Negative Symptoms 
(SANS).26 We calculated the SANS total score by sum-
ming all global rating items excluding the attention sub-
scale. For the SANS apathy score we summed the global 
rating items from the apathy and anhedonia subscale, 
and for the SANS diminished expression the global 
rating items from the alogia and affective flattening 
subscales.27 Apathy was assessed using the clinician ver-
sion of  the Apathy Evaluation Scale (AES28). Positive 
symptoms were assessed using the Positive and Negative 
Syndrome Scale (PANSS29). For the assessment of 
delusions in patients, we used the Psychotic Symptom 
Rating Scales,30 while in healthy participants we used the 
Magical Ideation Scale.31 Depression was assessed using 
the Calgary depression scale in patients with schizo-
phrenia32 and the Beck Depression Inventory (BDI) in 
healthy participants.33 Anhedonia was assessed using 
the Chapman scales for physical and social anhedonia34 
as well as the temporal experience of  pleasure scale.35 
Premorbid intelligence was assessed using a vocabulary-
based test.36
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fMRI Task
We employed a modified version of the CRRT.20 The 
CRRT-task allows an examination of brain activation 
during the anticipation of monetary gains and losses, 
which are dependent on performance in a simple discrim-
ination task (figure 1). We adopted a 2:1 ratio between 
amounts won and lost, because the individual value func-
tion for losses is generally steeper than for gains, ie, smaller 
potential losses acquire the same behavioral relevance as 
higher potential gains.37 The amount of money won or 
lost during each trial was calculated using an algorithm 
incorporating the participant’s previous reaction times 
(see supplementary figure S2). Error trials were defined 
as wrong reaction or omission of reaction and were not 
included in the subsequent analysis. Participants engaged 
in two 12-min sessions, each consisting of 80 trials. The 
maximum amount to be won was €36. To increase statis-
tical efficiency, trials were separated by jittered intertrial 
intervals which varied between 1 and 9 s, with a mean 
duration of 3.5 s. Each participant completed 25 practice 
trials before the task. The main behavioral outcome mea-
sure of the task was reward-related speeding, which was 
calculated by subtracting the reaction time during the 
neutral condition from the reaction time during experi-
mental conditions. Subjects were paid out the amount of 
money won during the task, and no additional financial 
compensation was offered.
fMRI Acquisition
Images were collected using a 1.5-Tesla Siemens Magnetom 
AvantoMRI system (Siemens Healthcare, Erlangen, 
Germany). 365 T2*-weighted, echo-planar images of the 
entire brain were acquired in each of the 2 runs. In order to 
minimize susceptibility artifacts in the orbitofrontal cor-
tex, 27 oblique slices of 4 mm thickness with a 30° angle 
relative to the anterior–posterior-commissure axis were 
acquired with the following parameters: TR 2280ms, TE 
40 ms, flip angle 90°, field of view 192 × 192 mm, matrix 
64 × 64, and voxel size 3 × 3 × 4 mm3. Participants viewed 
visual stimuli on a projection screen via a mirror fixed to 
the head coil and responded with the right hand using a 
button box. Following the functional scans, high resolu-
tion T1 weighted images were acquired using the three-
dimensional MPRAGE sequence with isotropic voxel 
size (160 slices, voxel size 1 × 1 × 1 mm, TR 1810 ms, TE 
3.07 ms, 15° flip angle, and field of view 256 × 256 mm) for 
anatomical reference.
fMRI Preprocessing
fMRI data were analyzed using SPM5 (Statistical 
Parametric Mapping, Wellcome Department of Cognitive 
Neurology). Functional images were checked manually 
for artifacts and corrected for differences in slice acquisi-
tion timing. Furthermore, all images were realigned with 
the allowed motion limited to ±4 mm translation and to 
±3° rotation over the whole experiment, and unwarped 
to correct for artifacts due to susceptibility-by-move-
ment interaction. Both functional and structural images 
were normalized to the Montreal Neurological Institute 
(MNI) T1 template. Functional images were spatially 
smoothed with a kernel of 8 mm full-width at half  maxi-
mum. Low-frequency signal drifts were removed using a 
128-s high-pass filter.
Statistical Analysis
On the first level of analysis, fMRI data were analyzed 
with a general linear model approach. Separate regres-
sors were included for the 5 different anticipation phases 
(anticipation of €2, anticipation of 40 cents, anticipation 
of minus €1, anticipation of minus 20 cent, and anticipa-
tion of €0) and the 5 corresponding outcome phases, as 
explanatory variables convolved with the gamma-variate 
Fig. 1. Cued reinforcement reaction time task (CRRT). In each trial, participants saw 1 of 6 geometric figures (“cue”; duration of .750 
s), which indicated maximum possible monetary amount to be won (2 euro, 40 cent, 0 euro, depicted using circles) or lost (−1 euro, −20 
cent, 0 cent, depicting using squares). After a delay period (varying between 2.5 and 3 s), participants had to identify an outlier out of 
an array of 3 circles via button press (either left or right button). Immediately after target presentation, participants received feedback 
about the amount of money they had won/lost during the respective trial (feedback, 1.5 s). A red horizontal line indicated the amount of 
money won during the respective trial. The precise amount was presented adjacent to the red line.
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function described as implemented in SPM. Targets and 
error trials were included as additional regressors of no 
interest. For the analysis of reward anticipation, indi-
vidual contrast images corresponding to the effects of 
interest were subsequently constructed. This involved 
contrasting the anticipation of a high reward (€2) with 
the anticipation of €0 and the anticipation of a high loss 
(minus €1) with the anticipation of €0. Group compari-
sons were performed with a region of interest approach 
focusing on the VS. In addition, we performed a whole-
brain analysis to characterize reward related activity 
in the whole sample (patients and healthy participants, 
N = 60) using a one sample t test. Results of the whole 
brain analysis are reported at a family-wise error cor-
rected threshold of P < .05.
Region of Interest Analysis
In order to assess brain activation in the VS—our a pri-
ori region of interest—we used anatomical voxel-masks 
taken from a publication-based probabilistic MNI atlas 
as in previous studies.18,38 Mean percent signal change 
was extracted for the VS ROI using MarsBaR.39 In order 
to assess differences in reward related activity between all 
4 groups, we performed ANOVA analyses with these acti-
vation estimates as dependent variables. Least Significant 
Difference post hoc tests were performed to assess dif-
ferences in activation between groups. Furthermore, we 
employed Pearson correlations to investigate the associa-
tions between VS signal change and clinical variables.
Connectivity Analysis
We employed a psychophysiological interaction analysis 
(PPI) to assess functional coupling of the VS with each 
voxel in the whole brain during the anticipation of a high 
reward (€2) vs €0, corresponding to changes in experi-
mental conditions.40 The interaction term was defined 
by using the contrast “anticipation of a high reward 
(€2) vs €0.” We used an anatomical voxel mask of the 
VS (see ROI-analysis) as a seed mask at the individual 
level. To reduce effects induced by task-related variance 
or correlations with the seed-ROI regardless of task, we 
included both the task regressor and the VS time course 
as regressors of no interest. The resulting statistical maps 
were then used in a random effects group analysis. Voxels 
showing a significant coupling with the VS were reported 
(thresholded at P < .05 cluster level corrected, cluster 
defining threshold P < .001 uncorrected). To further 
specify the relation between PLS and connectivity with 
the VS, we performed a covariate analysis by including 
the group-level (ie, coding of each participant according 
to his or her group affiliation) as covariate-of-interest in 
our statistical design. We extracted parameter estimates 
from these regions in order to compute an ANOVA to 
assess group differences.
Results
Demographic and Clinical Data
Demographic, clinical, and behavioral data are sum-
marized in table 1. There were no significant differences 
between groups with respect to age, education, reaction 
times, or premorbid intelligence level. Apathy, total nega-
tive symptoms, and positive symptoms differed between 
groups with the low PLS group showing the lowest level of 
symptoms and the schizophrenia group the highest score.
Behavioral Data
There were no significant differences between groups with 
respect to the total amount of money earned. Participants 
in all groups showed reward-related speeding in the win 
and loss conditions (supplementary figure S4). No dif-
ference in reward-related speeding between groups was 
observed (Fs < 1.5, P > .1).
fMRI—Local Activation in the VS
The focus of this analysis was regional activation in the 
VS ROI. The results of the whole-brain analysis are 
given in figure 2A and supplementary table S1 and reflect 
expected regions of the reward system.
We observed significant group differences in VS activ-
ity during the anticipation of €2 compared with €0 
(F = 2.97, P = .04, figure 2B), suggesting lower VS activ-
ity in groups with higher PLS. Post hoc tests suggest a 
significant difference between the low PLS group and the 
high PLS group (95% CI: 0.05, 0.37), as well as between 
the low PLS group and patients with schizophrenia (95% 
CI: 0.03, 0.33). We did not observe a significant difference 
between the high PLS group and patients with schizo-
phrenia (95% CI: −.017, 0.11).
There were no significant effects of gender, smoking, 
education years, or premorbid intelligence as covariates. 
Moreover, there was no significant correlation between 
chlorpromazine equivalents and VS activity during 
the reward anticipation in the patient group (r  =  −.14, 
P  =  .521). Additionally, we performed an explorative 
ANOVA to compare whole brain activity during the 
anticipation of €2 compared with €0 between groups. We 
did not observe any additional group differences.
We observed a similar pattern during the anticipation 
of a possible loss of €1 compared with €0, which however 
only reached trend-level significance (F = 2.2, P = .1).
Correlation Between Ventral Striatal Activation 
and Apathy
We observed a negative correlation between percent 
signal change in the right VS ROI during the anticipa-
tion of €2 vs no reward, and the level of apathy (AES: 
r = −.293, P =  .023, SANS apathy subscale: r = −.336, 
P = .009) (figure 3). There were no significant correlations 
1374
J. J. Simon et al
Table 1. Demographical Data, Psychopathology Ratings, and Task Performance
Healthy Controls
Low Symptom  
Expression
Average Symptom  
Expression
High Symptom  
Expression
Patients with 
Schizophrenia
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Difference  
Between Groups
Age (years) 25.5 (8.5) 26.4 (5.3) 28 (9) 30.3 (7.3) F = 1.4
N, Gender N = 12. 8 females N = 14. 8 females N = 11. 8 females N = 23. 8 females X2 = 5.8
MWT-B 30 (4) 28 (3) 30 (3) 28 (5) F = .9
Education (years) 14.9 (2) 16.3 (1.8) 15.8 (3.9) 15.4 (4.2) F = .4
Number of smokers 1 1 1 11 F = 4.9
Chlorpromazine equivalent 585 (402)
PAS 7 (6) 10 (6) 10 (7) 11 (7) F = .8
SAS 6 (5) 9 (5) 13 (7) 11 (6) F = 3.4*
TEPS general 84 (7) 80 (10) 78 (10) 76 (13) F = 1.6
TEPS anticipation 49 (4) 42 (5) 43 (6) 42 (7) F = 3.8*
TEPS consummation 39 (6) 38 (6) 38 (6) 36 (7) F = .4
CAPE frequency 1.2 (0.1) 1.7 (0.2) 2.2 (0.2) 1.9 (0.3) F = 31.6***
CAPE severity 1.1 (0.1) 1.4 (0.2) 1.9 (0.3) 1.6 (0.3) F = 11.1***
AES 7.7 (4) 11.6 (5.5) 14.1 (6.5) 17.7 (7.2) F = 7.5***
PANSS positive 8.3 (1.1) 8.9 (1.9) 9.2 (2.2) 10.5 (3.2) F = 3.3*
PANSS negative 7.6 (1.2) 9.2 (2.5) 9.9 (3) 14.8 (8.5) F = 6.9***
PANSS general 16.4 (0.8) 18.2 (2) 20.6 (5.4) 24.3 (6.2) F = 11.8***
SANS total 0.7 (1.1) 1.4 (1.9) 2.6 (3.7) 5.2 (4.1) F = 10.4***
SANS apathy 0.3 (0.6) 0.6 (1.6) 1.2 (2) 2.3 (2) F = 5**
SANS dimexp 0.4 (1) 0.7 (1.1) 1.5 (2.4) 2.7 (2.5) F = 5.3**
BDI 1.6 (1.4) 4.6 (3.7) 10.8 (9.6)
Calgary 4.2 (4)
MIS 2.1 (2.9) 2.5 (1.8) 5.5 (2.5)
PSYRATS 5 (5.5)
RRS win −0.035 (0.045) −0.05 (0.055) −0.029 (0.026) −0.042 (0.032) F = .9
RRS lose −0.029 (0.043) −0.041 (0.052) −0.027 (0.024) −0.027 (0.027) F = .5
Total win (euros) 29 (6) 29 (6) 29 (4) 28 (7) F = .1
Note: Values given as mean ± SD. MWT-B, vocabulary-based test for the assessment of premorbid intelligence; RRS, reward related 
speeding; PAS/SAS, Physical and social anhedonia scales; TEPS, Temporal experience of pleasure scale; CAPE, Community assessment 
of psychotic experiences; AES, Apathy evaluation scale; PANSS, Positive and negative symptom scale; SANS, Scale for the assessment of 
negative symptoms; BDI, Beck depression inventory; MIS, Magic ideation scale; PSYRATS, Psychotic symptom rating scales.
***P < .001, **P < .01, *P < .05.
Fig. 2. (A) Activation map of the contrast high reward (€2) anticipation vs no reward anticipation for all pooled participants. The threshold 
was set at P < .05 FWE corrected. The T-Map was overlaid on a normalized structural image averaged across all participants. The VS ROI 
is outlined on the activation map. (B) Group differences in VS signal change for high reward vs no reward anticipation, error bars depict SD.
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between PANSS positive symptoms and VS activation. In 
addition, there were no significant correlations between 
VS activation during loss anticipation and any psycho-
pathological variable. VS activity was also negatively cor-
related with CAPE scores (see supplementary results S1). 
Furthermore, we observed a negative correlation between 
BDI scores and VS activity in healthy participants (see 
supplementary results S1).
Ventral Striatal Connectivity During the Anticipation 
of a Reward
Connectivity analysis in the whole sample showed a 
significant functional coupling of the right VS with the 
bilateral thalamus (left thalamus: −12, −18, 8, t = 5.31, 
right thalamus: 15, −15, 4, t = 4.3), and anterior cingulate 
cortex (−9, 15, 32, t = 4.25). Restricting the connectiv-
ity analysis to the group of healthy participants (N = 37) 
revealed additional areas in the medial OFC (mOFC) 
(−12, 63, 0, t = 4.81), dorsal striatum (right DS, 15, 9, 12, 
t = 5.08), bilateral insula (left insula: −45, 12, 4, t = 5.41, 
right insula: 39, 21, 4, t = 4.51), and dorsal lateral pre-
frontal cortex (left, −39, 48, 24, t = 5.49).
Furthermore, our regression analysis revealed that con-
nectivity with the mOFC (−12, 63, 0, t = 4.2), left thalamus 
(−6, −12, 8, t = 5.04), and right DS (18, 9, 12, t = 5.09) 
was modulated by the group-regressor; lower PLS was 
related to stronger connectivity with these regions (fig-
ure  4A). An ANOVA revealed significant group differ-
ences in the mOFC using extracted parameter estimates 
(F = 8.6, P < .001, figure 4B). Post hoc tests revealed that 
the significant effect in the mOFC was mainly driven by 
pronounced differences in connectivity between patients 
and the different healthy control groups (Ps < 0.002), the 
three healthy groups did not differ (Ps > 0.05). The group 
effect remained significant after controlling for the effect 
Fig. 3. Correlation between percent signal change in the right VS ROI during the anticipation of €2 vs no reward and apathy scores
Fig. 4. (A) Group differences in functional coupling of the VS with the mOFC calculated with a covariate analysis (inclusion of 
the group-level as covariate of interest in the statistical design, P < .05 cluster level corrected, cluster defining threshold P < .001 
uncorrected). The T-Map was overlaid on a normalized structural image averaged across all participants. (B) Strength of connectivity  
for each group, error bars depict SD. The ROI used for the extraction of parameter estimates is outlined on the activation map.
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of smoking (F = 3.6, P = .019) and differences in variabil-
ity of local VS activation (F = 6.4, P = .003).
Discussion
To our knowledge, this is the first neuroimaging study to 
include healthy participants with different levels of PLS 
and patients with manifest schizophrenia. We show that 
higher PLS were associated with lower activation in the 
VS during the anticipation of rewards, irrespective of 
diagnostic status. Across groups, apathy—a core nega-
tive symptom—was the symptom most strongly associ-
ated with ventral striatal activation. However, in contrast 
to local activation of the VS, its connectivity with the 
medial orbitofrontal cortex was specifically altered in 
patients with schizophrenia.
In our healthy participants, ventral striatal activation 
became smaller with increasing PLS as assessed by the 
CAPE. Thus, the continuous expression of PLS across 
the different groups was paralleled by decreased ventral 
striatal activation. Importantly, healthy participants with 
high PLS seem to differ from those with low PLS, but not 
from patients with schizophrenia. This suggests that with 
respect to local brain response to reward anticipation in 
the VS, patients with schizophrenia do not show a quali-
tative difference to participants without a psychotic dis-
order, but rather lie at one end of the general population 
distribution.
The finding that patients with schizophrenia did not 
show lower ventral striatal activation than healthy partici-
pants with high PLS was somewhat unexpected. However, 
this lack of difference may relate to treatment effects. First, 
as a consequence of treatment, patients with schizophre-
nia did show higher symptom levels only in some scales. 
Second, treatment with atypical antipsychotics has been 
shown to normalize responses of the reward system.15
Furthermore, we found that across groups, lower activ-
ity in the VS during the anticipation of a reward is related 
to apathy. This observation extends previous findings in 
patients with schizophrenia.17,18 In functional terms, the 
VS has mainly been considered to code the incentive 
salience or “wanting” of a reward, while it might also 
have a role in coding the “liking” of a reward.41 A dys-
functional coding of incentive salience has been discussed 
as a possible underlying factor for reduced goal-directed 
behavior in patients with schizophrenia.17 In contrast to 
previous studies, we assessed negative symptoms and apa-
thy not only in patients, but also in healthy participants 
with different levels of PLS. While negative symptoms 
have traditionally been thought to be specific to schizo-
phrenia, it has more recently been suggested that nega-
tive symptoms can be observed outside the schizophrenia 
spectrum.5 Our data show not only a considerable overlap 
in negative symptom expression across groups, but also a 
continuous association between apathy and ventral stria-
tal activation.
Group differences in ventral striatal activation and the 
correlation with apathy were more pronounced during 
win than during loss anticipation. This suggests that over-
all the effects were mainly driven by the association of 
ventral striatal response with reward and negative symp-
toms, specifically apathy.16,18 One possible explanation for 
the stronger relationship of apathy with rewards relates 
to the focus on reward seeking and approach motiva-
tion in most apathy scales. It is an open question whether 
impaired motivation to avoid punishment should also be 
considered as a part of apathy, which would be expected 
to be more closely related to ventral striatal responses to 
loss anticipation.42
In addition, there was no association of positive symp-
toms with striatal response. Thus, these findings do not 
directly support an explanation in terms of aberrant 
salience, which would associate positive symptoms with 
both wins and losses.43 However, the low variance in posi-
tive symptom expression might account for these nega-
tive findings. In addition, it is possible that the 2:1 ratio 
between amounts won and lost adopted in our study 
failed to induce sufficient behavioral relevance or salience 
of potential losses.
During anticipation of a reward vs no reward, we found 
aberrant connectivity between the VS and the mOFC spe-
cifically in the patient group. In contrast to local brain acti-
vation in the VS, connectivity did not differ significantly 
between healthy groups with different levels of PLS. Thus, 
dysfunctional connectivity, which has been put forward as 
a core neurophysiological mechanism underlying schizo-
phrenia,44,45 shows a pattern consistent with a categorical 
difference between patients with schizophrenia and persons 
without a psychotic disorder. Dysfunctional frontostriatal 
connectivity has been related to maladaptive reinforcement 
learning,46 which has been consistently observed in patients 
with schizophrenia.47,48 Abnormal functional integration 
within the reward system may therefore represent a pathog-
nomonic aspect of schizophrenia.
Our results for local striatal activation during the antic-
ipation of a reward support a dimensional view, which 
is consistent with a number of studies suggesting a con-
tinuous association with dimensions of human behav-
ior and personality.49,50 These findings have mostly been 
interpreted in terms of variations in dopaminergic neuro-
transmission. In contrast, the connectivity analysis sup-
ports a categorical difference between “healthy” persons 
and patients with schizophrenia. Structural white-matter 
changes and N-Methyl-D-aspartate (NMDA)-receptor 
dysfunction have been proposed as pathomechanisms 
underlying aberrant functional coupling.45 Whether the 
latter mechanisms show any specificity for schizophrenia 
remains to be elucidated.
There are several limitations to our study. First, 
because we used a web-based questionnaire to identify 
healthy participants with differing degrees of PLS, we 
had no guarantee as to whether or not participants were 
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accurately describing their own experiences. Nonetheless, 
the subsequent psychometric assessment confirmed the 
validity of our groups. Second, splitting the healthy par-
ticipants into groups with different PLS led to relatively 
small cell sizes, which reduced the power to detect dif-
ferences between groups. Third, because we did not cor-
rect post hoc tests and correlational analyses for multiple 
comparisons, our findings should be considered as explor-
atory and need to be replicated. Fourth, all patients were 
medicated with antipsychotics, which might have affected 
differences between healthy and patient groups, although 
chlorpromazine equivalent dosage was not related to ven-
tral striatal activation or connectivity. It is nevertheless 
important to consider the possibility that the influence of 
medication could be categorical and not linear. Fifth, it 
has to be noted that although we included both the task 
regressor and VS time course as regressors of no interest 
in our PPI analysis, unaccounted task-related variance 
stemming from the unmodeled outcome phase could 
have influenced the observed activation in the mOFC.
In conclusion, the present study provides evidence for 
both continuous and discontinuous neural substrates of 
symptom expression across patients with schizophrenia 
and the general population. Dysfunctional local activa-
tion of the VS depends less on diagnostic status than on 
the degree of symptom expression. Lifetime PLS, current 
negative symptoms as well as symptoms of depression 
in nonclinical participants were associated with reduced 
striatal activation. Thus, local activation of the VS shows 
a pattern consistent with a psychosis continuum. In con-
trast, aberrant connectivity in the reward system is specific 
to patients with schizophrenia, thereby supporting a cat-
egorical view. The investigation of samples across a broad 
range of nonclinical and clinical symptom expression is a 
promising avenue for addressing the neural basis of symp-
tom distributions observed in epidemiological samples.
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